Cargando…

Immune Checkpoints Inhibitors and Chemotherapy as First-Line Treatment for Metastatic Urothelial Carcinoma: A Network Meta-Analysis of Randomized Phase III Clinical Trials

SIMPLE SUMMARY: On the basis of the efficacy and tolerable safety profiles of immune checkpoints inhibitors (ICIs) in second-line metastatic urothelial carcinoma (mUC) patients, some emerging clinical trials focus on the first-line treatment. Thus, we conducted a network meta-analysis (NMA) to asses...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Hsiao-Ling, Chan, Vinson Wai-Shun, Tu, Yu-Kang, Chan, Erica On-Ting, Chang, Hsiu-Mei, Juan, Yung-Shun, Teoh, Jeremy Yuen-Chun, Lee, Hsiang Ying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8005008/ https://www.ncbi.nlm.nih.gov/pubmed/33807108 http://dx.doi.org/10.3390/cancers13061484

Ejemplares similares

Lymph node dissection for upper tract urothelial carcinoma: A systematic review
por: Chan, Vinson Wai-Shun, et al.
Publicado: (2020)

Comparison of add-on medications for persistent storage symptoms after α-blocker treatment in BPH patients – a network meta-analysis
por: Su, Yi-Ting, et al.
Publicado: (2023)

Outlook into the future of front-line immune checkpoint inhibition in metastatic urothelial carcinoma
por: Brown, Jason R., et al.
Publicado: (2021)

A systematic review and meta-analysis on delaying surgery for urothelial carcinoma of bladder and upper tract urothelial carcinoma: Implications for the COVID19 pandemic and beyond
por: Leow, Jeffrey J., et al.
Publicado: (2022)

A systematic review on COVID-19: urological manifestations, viral RNA detection and special considerations in urological conditions
por: Chan, Vinson Wai-Shun, et al.
Publicado: (2020)

Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy
por: Tassinari, Elisa, et al.
Publicado: (2022)

Kidney and Cancer Outcomes with Standard Versus Alternative Chemotherapy Regimens for First-Line Treatment of Metastatic Urothelial Carcinoma
por: Côté, Gabrielle, et al.
Publicado: (2023)

Third-Line Chemotherapy for Metastatic Urothelial Cancer: A Retrospective Observational Study
por: Di Lorenzo, Giuseppe, et al.
Publicado: (2015)

Does power setting impact surgical outcomes of holmium laser enucleation of the prostate? A systematic review and meta-analysis
por: Pirola, Giacomo Maria, et al.
Publicado: (2022)

First-line Immune Checkpoint Inhibitor Versus Immune Checkpoint Inhibitor With Chemotherapy for Cisplatin-ineligible Metastatic Urothelial Carcinoma: Evidence From a Real-world, Multicenter Analysis
por: Lin, Chang-Ting, et al.
Publicado: (2022)

First-line immune checkpoint inhibitors for patients with metastatic urothelial carcinoma treated in routine clinical practice
por: Naito, Renato, et al.
Publicado: (2020)

A pilot study of gemcitabine and paclitaxel as third-line chemotherapy in metastatic urothelial carcinoma
por: Naiki, Taku, et al.
Publicado: (2017)

Biomarkers of the Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma
por: Chen, Siteng, et al.
Publicado: (2020)

Checkpoint Inhibition for Metastatic Urothelial Carcinoma After Chemotherapy—Real-World Clinical Impressions and Comparative Review of the Literature
por: Fuhrmann, Christian, et al.
Publicado: (2020)

Tailored Selection of First-Line Cisplatin-Based Chemotherapy in Patients with Metastatic Urothelial Carcinoma of Bladder
por: Hsieh, Meng-Che, et al.
Publicado: (2016)

A Comprehensive Review of US FDA-Approved Immune Checkpoint Inhibitors in Urothelial Carcinoma
por: Hsu, Fu-Shun, et al.
Publicado: (2017)

A Case of Metastatic Urothelial Carcinoma Treated with Pemetrexed as Third-Line Chemotherapy with Discussion and Literature Review
por: Iida, Keitaro, et al.
Publicado: (2015)

Phase II trial of palbociclib in patients with metastatic urothelial cancer after failure of first-line chemotherapy
por: Rose, Tracy L., et al.
Publicado: (2018)

Gemcitabine and docetaxel as second-line chemotherapy in elderly patients with metastatic urothelial carcinoma: a retrospective analysis
por: Naiki, Taku, et al.
Publicado: (2018)

Combination Biomarker of Immune Checkpoints Predict Prognosis of Urothelial Carcinoma
por: Tsai, Chung-Ying, et al.
Publicado: (2021)

5α-reductase inhibitors impact prognosis of urothelial carcinoma
por: Wang, Chien-Sheng, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors and Long-term Survival of Patients With Metastatic Urothelial Cancer
por: Zhu, Alec, et al.
Publicado: (2023)

The prognostic impact of bone metastasis in patients with metastatic urothelial carcinoma treated with first-line platinum-based chemotherapy
por: Alqaisi, Husam A., et al.
Publicado: (2022)

How to manage patients with suspected upper tract urothelial carcinoma in the pandemic of COVID-19?
por: Lee, Hsiang-Ying, et al.
Publicado: (2021)

Paclitaxel and carboplatin chemotherapy after platinum-based chemotherapy and pembrolizumab for metastatic urothelial carcinoma
por: Furubayashi, Nobuki, et al.
Publicado: (2021)

Metastatic Urothelial Carcinoma from Transplanted Kidney with Complete Response to an Immune Checkpoint Inhibitor
por: Chiang, Ryan S., et al.
Publicado: (2020)

Subsequent Systemic Therapy following Platinum and Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma
por: Hong, Joohyun, et al.
Publicado: (2022)

Gemcitabine maintenance versus observation after first-line chemotherapy in patients with metastatic urothelial carcinoma: a retrospective study
por: Kim, Hyunho, et al.
Publicado: (2020)

Atezolizumab plus platinum-based chemotherapy as first-line therapy for metastatic urothelial cancer: A cost-effectiveness analysis
por: Liu, Xiaoyan, et al.
Publicado: (2022)

Second-Line Systemic Treatment for Metastatic Urothelial Carcinoma: A Network Meta-Analysis of Randomized Phase III Clinical Trials
por: Yoon, Hyun Sik, et al.
Publicado: (2019)

Administration of Enfortumab Vedotin after Immune-Checkpoint Inhibitor and the Prognosis in Japanese Metastatic Urothelial Carcinoma: A Large Database Study on Enfortumab Vedotin in Metastatic Urothelial Carcinoma
por: Kawahara, Takashi, et al.
Publicado: (2023)

Primary renal angiosarcoma mimicking urothelial carcinoma – A case report and literature reviews
por: Chang, Che-Wei, et al.
Publicado: (2020)

Infigratinib in Early-Line and Salvage Therapy for FGFR3-Altered Metastatic Urothelial Carcinoma
por: Lyou, Yung, et al.
Publicado: (2022)

Novel risk group stratification for metastatic urothelial cancer patients treated with immune checkpoint inhibitors
por: Shabto, Julie M., et al.
Publicado: (2020)

Sex hormones influence survival of patients with metastatic urothelial carcinoma undergoing immune checkpoint therapy
por: Lindner, Andrea Katharina, et al.
Publicado: (2023)

Immune checkpoint inhibitors for urothelial carcinoma
por: Kim, Hyung Suk, et al.
Publicado: (2018)

Systematic Review and Network Meta-Analysis of Immune Checkpoint Inhibitors in Combination with Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Carcinoma
por: Chen, Hsiao-Ling, et al.
Publicado: (2020)

Metastatic urothelial carcinoma()()
por: Gómez-Moyano, Elisabeth, et al.
Publicado: (2021)

Impact of relative dose intensity in gemcitabine–cisplatin chemotherapy for metastatic urothelial carcinoma
por: Kohei, Naoki, et al.
Publicado: (2018)

Outcome of maintenance systemic chemotherapy with drug-free interval for metastatic urothelial carcinoma
por: Abe, T, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_7okqod4aj686osl576gd9v705t